SynthesisCardiovascular & hematological disorders drug targets2026
New Advances in Diagnosis, Phytonano, and Chinese Medicine-based Therapy for Atherosclerosis- A Systematic Review.
Synthesis in Cardiovascular & hematological disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAtherosclerosis is significantly impacted by immune and inflammatory responses. Data suggest that immunity plays a greater role in atherosclerosis by closely regulating its development and lipid accumulation. The hallmarks are vascular smooth muscle expansion, cell death, destruction, swelling, and localized inflammation. The present review aims to explore the latest advances in diagnosis, phytonano, and Chinese medicine-based therapy for atherosclerosis.
methodsThe data were collected from various platforms, including PubMed, SciFinder, Google Scholar, Elsevier, and Bentham Science.
resultsIn both in vitro and in vivo investigations, the bioactive molecules from plant extracts have been demonstrated to have a wide range of health-promoting activities, including antioxidant, immune-boosting, and many more. Nanomedicines have made significant strides, providing prospects for accurate, customized diagnosis and therapy. These targeted and sustained deliveries make compounds reach the predetermined dose and time. DISCUSSION: The potential of engineered bio-nonmaterials to deliver therapeutic and imaging substances to atherosclerotic plaques is actively studied and has been found generally effective.
conclusionThe current review presents risk factors, diagnosis, pathogenesis, and treatment with novel drug delivery agents, such as nanoparticles and liposomes, along with their mechanisms of action. Nanoparticles improved plague stability by 35-50%. Apart from this, we also compiled the Chinese formulations, their mechanisms of action, and the models used.
Indexed as
Identifiers
43015583What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.